Michelle Doig left the role of Director at BridgeBio Oncology Therapeutics, Inc., effective June 16, 2026. As of November 6, 2026, BridgeBio Oncology Therapeutics, Inc. has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 23, 2026 to November 5, 2026, naming 2 departures (Form 8-K, June 22, 2026).
Who owns BridgeBio Oncology Therapeutics, Inc.?
On the record Who owns BridgeBio Oncology Therapeutics, Inc.? Owners, funding and legal record
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like BridgeBio Oncology Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-11-05
- · In / out: Out · Person: Michelle Doig · Role: Director · Effective: 2026-06-16 · 8-K, 2026-06-22
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-29
- · In / out: Out · Person: Eli Wallace · Role: Director · 8-K, 2026-04-23
BridgeBio Oncology Therapeutics, Inc. reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-23 to 2026-11-05. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as BridgeBio Oncology Therapeutics, Inc. files it.
Also on the record for BridgeBio Oncology Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 6, 2026 | Stake report, Schedule 13D/A, by Bihua Chen | 22.32% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Citadel Advisors LLC | 3.2% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 1.88% of the class | 5%+ stakes | Source |
| September 3, 2025 | Stake report, Schedule 13G, by BC Global Opportunities IX LP | 5.5% of the class | 5%+ stakes | Source |
| August 18, 2025 | Stake report, Schedule 13D, by BridgeBio Pharma LLC | 17.5% of the class | 5%+ stakes | Source |
| August 18, 2025 | Stake report, Schedule 13G, by Deerfield Management Company, L.P. | 6.17% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13D/A, by Helix Holdings II LLC | 22.6% of the class | 5%+ stakes | Source |
| July 30, 2025 | Stake report, Schedule 13G/A, by Millennium Management LLC | 4.7% of the class | 5%+ stakes | Source |
| July 24, 2025 | Stake report, Schedule 13G, by Sculptor Capital LP | 5.12% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs BridgeBio Oncology Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on BridgeBio Oncology Therapeutics, Inc. and the records around it.
BridgeBio Oncology Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Bihua Chen also filed stake reports on 1 other company: MoonLake Immunotherapeutics (Oct 2025)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Sculptor Capital LP also filed stake reports on 40 other companies: Helix Acquisition Corp. III (Oct 2026), Live Oak Acquisition Corp. VI (Oct 2026), Amanat Acquisition Corp (Aug 2026)
Watch BridgeBio Oncology Therapeutics, Inc.
Get an email when BridgeBio Oncology Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BridgeBio Oncology Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BridgeBio Oncology Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BridgeBio Oncology Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-05 | Reported | not named in the filing | 8-K, 2026-11-05 | ||
| 2026-06-22 | Out | Director | 2026-06-16 | 8-K, 2026-06-22 | |
| 2026-04-29 | Reported | not named in the filing | 8-K, 2026-04-29 | ||
| 2026-04-23 | Out | Director | 8-K, 2026-04-23 |
Who leads BridgeBio Oncology Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Michelle Doig, departure reported, effective 2026-06-16 (filed 2026-06-22). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on BridgeBio Oncology Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at BridgeBio Oncology Therapeutics, Inc., with the record behind each one.
Find candidates like Director at BridgeBio Oncology Therapeutics, Inc.Every change, in the filing's words
Reported
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- (b) On October 30, 2026, Yong Ben, M.D., M.B.A. provided notice of his resignation as the Chief Medical and Development Officer of BridgeBio Oncology Therapeutics, Inc. (the "Company"), effective January 8, 2027.
- Dr. Ben's resignation was not due to any disagreement regarding the operations, policies or practices of the Company.
Departing: Michelle Doig, Director, effective 2026-06-16
On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the "Company"), of her resignation as a member of the Board of Directors of the Company (the "Board") upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting").
- Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Ms. Doig's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Reported
Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- On April 27, 2026, the Company entered into a consulting agreement (the "Consulting Agreement") with Dr. Wallace, pursuant to which Dr. Wallace will provide the Company with advisory services regarding the Company's research and development programs, effective retroactively as of April 21, 2026 (the "Effective Date") through the date twelve (12) months thereafter (the "Consulting Term"), unless terminated earlier pursuant to the terms of the Consulting Agreement.
- Dr. Wallace's exclusive compensation under the Consulting Agreement will be the continued vesting of the outstanding equity awards that he held as of the Effective Date pursuant to the applicable equity incentive plans of the Company, subject to Dr. Wallace providing services to the Company through each applicable vesting date, in accordance with the applicable equity incentive plans and the applicable award agreements.
- Dr. Wallace's outstanding stock option grants may also, to the extent vested and exercisable as of the date of termination of the Consulting Agreement, be exercised until the earlier of (i) the date two (2) years after the date of termination of Dr. Wallace's continued services to the Company as an employee or consultant and (ii) the original expiration date of the applicable stock option grant.
Departing: Eli Wallace, Director
Additionally, on April 20, 2026, Dr. Wallace resigned from his position as a member of the Board and as a Class III director, and the Board appointed Dr. Beltran as a Class III director to fill the vacancy created by Dr. Wallace's resignation, effective immediately.
- Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Appointment Chief Executive Officer and Director On April 20, 2026, the Board of Directors (the "Board") of BridgeBio Oncology Therapeutics, Inc. (the "Company") approved the appointment of Pedro Beltran, Ph.D., as the Company's President and Chief Executive Officer ("CEO") (and as the Company's principal executive officer), effective immediately.
- Dr. Beltran succeeds Eli Wallace, Ph.D. in these positions.
- It is expected that Dr. Wallace will continue to serve as an advisor to the Company following his term as President and CEO.
- Dr. Wallace's resignation was not the result of any disagreement with the policies, procedures or practices of the Company.
- The Board thanks Dr. Wallace for his years of service to the Company.
- Dr. Beltran, age 55, served as Chief Scientific Officer of the Company (including the Company's predecessor, TheRas, Inc.) since April 2024 until his appointment as President and CEO.
- Previously, Dr. Beltran served as Chief Scientific Officer of BridgeBio Pharma, Inc. (Nasdaq: BBIO) from July 2023 to April 2024, and as Senior Vice President of Biology from July 2020 to July 2023.
Tools for this story
Each opens in a new tab, filled in for BridgeBio Oncology Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.